Just a couple months ago, Janet Yellen issued a warning that biotechnology may be in a bubble. Tuesday, the iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) was 20% higher. While Janet Yellen was wrong at the time, we should all remember that Alan Greenspan issued the same warning on Dot.com companies in the late 1990s. He was early on that call but ultimately right.
Based on technical analysis, it appears biotechnology may have reached a top Tuesday. Why?
First, the daily chart put in a significant top signal (doji). Yesterday, the move confirmed as the index declined. This came on the back of an explosive move known to traders and investors as a blow-off top (previous 2 weeks). In addition, stocks like Amgen, Inc. (NASDAQ:AMGN) and Gilead Sciences, Inc. (NASDAQ:GILD) reported earnings. Significant distribution appears to be taking hold on these names. Ultimately, while timing is not Fed Chair Janet Yellen's forte, nor was it Greenspan's. It is important to take it as an important heads up. Combining their viewpoint and the charts could yield a significant shorting opportunity worth 30% or more.
